Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.

Iacobino A, Giannoni F, Pardini M, Piccaro G, Fattorini L.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00273-19. doi: 10.1128/AAC.00273-19. Print 2019 Jul.

2.

Revisiting problems and solutions to decrease Mycobacterium tuberculosis pyrazinamide false resistance when using the Bactec MGIT 960 system.

Mustazzolu A, Piersimoni C, Iacobino A, Giannoni F, Chirullo B, Fattorini L.

Ann Ist Super Sanita. 2019 Jan-Mar;55(1):51-54. doi: 10.4415/ANN_19_01_09.

3.

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells.

Tanner R, Smith SG, van Meijgaarden KE, Giannoni F, Wilkie M, Gabriele L, Palma C, Dockrell HM, Ottenhoff THM, McShane H.

J Immunol Methods. 2019 Jun;469:1-10. doi: 10.1016/j.jim.2019.01.006. Epub 2019 Jan 31.

4.

Activity of DNA-targeted C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions.

Iacobino A, Giannoni F, Fattorini L, Brucoli F.

J Antibiot (Tokyo). 2018 Sep;71(9):831-834. doi: 10.1038/s41429-018-0068-5. Epub 2018 May 24.

PMID:
29795520
5.

Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016.

Mustazzolu A, Borroni E, Cirillo DM, Giannoni F, Iacobino A; Italian Multicentre Study on Resistance to Antituberculosis Drugs (SMIRA), Fattorini L.

Eur Respir J. 2018 Jul 19;52(1). pii: 1800070. doi: 10.1183/13993003.00070-2018. Print 2018 Jul. No abstract available.

6.

Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.

Mustazzolu A, Iacobino A, Giannoni F, Piersimoni C; Italian Multicentre Study on Resistance to Antituberculosis Drugs (SMIRA) Group, Fattorini L.

J Clin Microbiol. 2017 Dec;55(12):3552-3553. doi: 10.1128/JCM.01437-17. Epub 2017 Sep 13. No abstract available.

7.

Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli.

Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L.

Int J Mycobacteriol. 2017 Jul-Sep;6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17. Review.

8.

Activity of drugs against dormant Mycobacterium tuberculosis.

Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S94-S95. doi: 10.1016/j.ijmyco.2016.09.061. Epub 2016 Nov 12.

9.

Silencing peroxiredoxin-2 sensitizes human colorectal cancer cells to ionizing radiation and oxaliplatin.

Cerda MB, Lloyd R, Batalla M, Giannoni F, Casal M, Policastro L.

Cancer Lett. 2017 Mar 1;388:312-319. doi: 10.1016/j.canlet.2016.12.009. Epub 2016 Dec 18.

PMID:
28003121
10.

Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.

Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02296-16. doi: 10.1128/AAC.02296-16. Print 2017 Mar.

11.

Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system.

Piersimoni C, Mustazzolu A, Iacobino A, Giannoni F, Santoro G, Gherardi G, Del Giudice A, Perna R, Fattorini L.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1677-1680.

PMID:
27931346
12.

Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation.

Iona E, Pardini M, Mustazzolu A, Piccaro G, Nisini R, Fattorini L, Giannoni F.

J Microbiol. 2016 Aug;54(8):565-72. doi: 10.1007/s12275-016-6150-4. Epub 2016 Aug 2.

PMID:
27480637
13.

Tuberculosis in migrants from 106 countries to Italy, 2008-2014.

Fattorini L, Mustazzolu A, Borroni E, Piccaro G, Giannoni F, Cirillo DM; Italian Multicentre Study on Resistance to Antituberculosis Drugs (SMIRA) Group.

Eur Respir J. 2016 Apr;47(4):1273-6. doi: 10.1183/13993003.01844-2015. Epub 2016 Feb 4. No abstract available.

14.

Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Piccaro G, Poce G, Biava M, Giannoni F, Fattorini L.

J Antibiot (Tokyo). 2015 Nov;68(11):711-4. doi: 10.1038/ja.2015.52. Epub 2015 May 6. No abstract available.

PMID:
25944535
15.

Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosis.

Piccaro G, Pietraforte D, Giannoni F, Mustazzolu A, Fattorini L.

Antimicrob Agents Chemother. 2014 Dec;58(12):7527-33. doi: 10.1128/AAC.03169-14. Epub 2014 Oct 6.

16.

Targeting dormant bacilli to fight tuberculosis.

Fattorini L, Piccaro G, Mustazzolu A, Giannoni F.

Mediterr J Hematol Infect Dis. 2013 Nov 19;5(1):e2013072. doi: 10.4084/MJHID.2013.072. Review.

17.

Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.

De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, Katebian B, Wherley J, Sahaghian A, Tu A, Grogan T, Elashoff D, Cooper LJ, Hollis RP, Kohn DB.

Hum Gene Ther. 2013 Oct;24(10):824-39. doi: 10.1089/hum.2012.202.

18.

Dormant Mycobacterium tuberculosis fails to block phagosome maturation and shows unexpected capacity to stimulate specific human T lymphocytes.

Mariotti S, Pardini M, Gagliardi MC, Teloni R, Giannoni F, Fraziano M, Lozupone F, Meschini S, Nisini R.

J Immunol. 2013 Jul 1;191(1):274-82. doi: 10.4049/jimmunol.1202900. Epub 2013 Jun 3.

19.

Mycobacterium tuberculosis may escape helper T cell recognition by infecting human fibroblasts.

Mariotti S, Sargentini V, Pardini M, Giannoni F, De Spirito M, Gagliardi MC, Greco E, Teloni R, Fraziano M, Nisini R.

Hum Immunol. 2013 Jun;74(6):722-9. doi: 10.1016/j.humimm.2013.02.005. Epub 2013 Feb 28.

PMID:
23459076
20.

Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.

Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X, Gjertson D, Baltimore D, Witte ON, Economou JS, Ribas A, Kohn DB.

Mol Ther. 2013 May;21(5):1044-54. doi: 10.1038/mt.2013.8. Epub 2013 Feb 5.

21.

Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Piccaro G, Giannoni F, Filippini P, Mustazzolu A, Fattorini L.

Antimicrob Agents Chemother. 2013 Mar;57(3):1428-33. doi: 10.1128/AAC.02154-12. Epub 2013 Jan 7.

22.

Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.

Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L.

J Clin Microbiol. 2013 Jan;51(1):291-4. doi: 10.1128/JCM.01838-12. Epub 2012 Oct 24.

23.

Drug-resistant tuberculosis among foreign-born persons in Italy.

Fattorini L, Mustazzolu A, Piccaro G, Pardini M, Filippini P, Giannoni F, Migliori GB, Sotgiu G, Borroni E, Cirillo DM; Italian Multicentre Study on Resistance to Antituberculosis Drugs Group.

Eur Respir J. 2012 Aug;40(2):497-500. No abstract available.

24.

Infection of human THP-1 cells with dormant Mycobacterium tuberculosis.

Iona E, Pardini M, Gagliardi MC, Colone M, Stringaro AR, Teloni R, Brunori L, Nisini R, Fattorini L, Giannoni F.

Microbes Infect. 2012 Sep;14(11):959-67. doi: 10.1016/j.micinf.2012.04.003. Epub 2012 Apr 14.

PMID:
22546526
25.

Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

Tarantal AF, Giannoni F, Lee CC, Wherley J, Sumiyoshi T, Martinez M, Kahl CA, Elashoff D, Louie SG, Kohn DB.

Mol Ther. 2012 May;20(5):1033-45. doi: 10.1038/mt.2011.312. Epub 2012 Jan 31.

26.

Activity of drugs against dormant Mycobacterium tuberculosis.

Piccaro G, Filippini P, Giannoni F, Scipione L, Tortorella S, De Vita D, Mellini P, Fattorini L.

J Chemother. 2011 Jun;23(3):175-8. No abstract available.

PMID:
21742589
27.

Endogenous PGE2 promotes the induction of human Th17 responses by fungal ß-glucan.

Gagliardi MC, Teloni R, Mariotti S, Bromuro C, Chiani P, Romagnoli G, Giannoni F, Torosantucci A, Nisini R.

J Leukoc Biol. 2010 Nov;88(5):947-54. doi: 10.1189/jlb.0310139. Epub 2010 Aug 31.

PMID:
20807707
28.

CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.

Dias P, Giannoni F, Lee LN, Han D, Yoon S, Yagita H, Azuma M, Sarawar SR.

J Virol. 2010 Aug;84(16):8241-9. doi: 10.1128/JVI.00784-10. Epub 2010 Jun 9.

29.

Carotid body tumors: radioguided surgical approach.

Martinelli O, Irace L, Massa R, Savelli S, Giannoni F, Gattuso R, Gossetti B, Benedetti-Valentini F, Izzo L.

J Exp Clin Cancer Res. 2009 Dec 10;28:148. doi: 10.1186/1756-9966-28-148.

30.

Mycobacteria exploit p38 signaling to affect CD1 expression and lipid antigen presentation by human dendritic cells.

Gagliardi MC, Teloni R, Giannoni F, Mariotti S, Remoli ME, Sargentini V, Videtta M, Pardini M, De Libero G, Coccia EM, Nisini R.

Infect Immun. 2009 Nov;77(11):4947-52. doi: 10.1128/IAI.00607-09. Epub 2009 Aug 31.

31.

Primary clearance of murine gammaherpesvirus 68 by PKCtheta-/- CD8 T cells is compromised in the absence of help from CD4 T cells.

Dias P, Shea AL, Inglis C, Giannoni F, Lee LN, Sarawar SR.

J Virol. 2008 Dec;82(23):11970-5. doi: 10.1128/JVI.01053-08. Epub 2008 Sep 25.

32.

CD40 engagement on dendritic cells, but not on B or T cells, is required for long-term control of murine gammaherpesvirus 68.

Giannoni F, Shea A, Inglis C, Lee LN, Sarawar SR.

J Virol. 2008 Nov;82(22):11016-22. doi: 10.1128/JVI.00919-08. Epub 2008 Sep 3.

33.

The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response.

Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Fattorini L, Del Giudice G, Cassone A.

Vaccine. 2008 Aug 5;26(33):4237-43. doi: 10.1016/j.vaccine.2008.05.050. Epub 2008 Jun 12.

PMID:
18584925
34.

Squamous cell carcinoma secondary to buruli ulcer.

Minutilli E, Orefici G, Pardini M, Giannoni F, Muscardin LM, Massi G, Sanguinetti M, Fadda G, Di Miceli D, Doglietto GB.

Dermatol Surg. 2007 Jul;33(7):872-5. No abstract available.

PMID:
17598858
35.

Isolation of Nocardia asiatica from cutaneous ulcers of a human immunodeficiency virus-infected patient in Italy.

Iona E, Giannoni F, Brunori L, de Gennaro M, Mattei R, Fattorini L.

J Clin Microbiol. 2007 Jun;45(6):2088-9. Epub 2007 Apr 19.

36.

The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.

Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L, Cassone A.

Cell Microbiol. 2007 Jun;9(6):1455-65. Epub 2007 Jan 22.

PMID:
17250590
37.

Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.

Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L.

Antimicrob Agents Chemother. 2007 Apr;51(4):1537-40. Epub 2007 Jan 22.

38.

Chemokine regulation of the inflammatory response to a low-dose influenza infection in CCR2-/- mice.

Wareing MD, Lyon A, Inglis C, Giannoni F, Charo I, Sarawar SR.

J Leukoc Biol. 2007 Mar;81(3):793-801. Epub 2006 Dec 19.

PMID:
17179466
39.

Interleukin-4 inhibits cyclo-oxygenase-2 expression and prostaglandin E production by human mature dendritic cells.

Teloni R, Giannoni F, Rossi P, Nisini R, Gagliardi MC.

Immunology. 2007 Jan;120(1):83-9. Epub 2006 Oct 24.

40.

Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis.

Pardini M, Giannoni F, Palma C, Iona E, Cafaro A, Brunori L, Rinaldi M, Fazio VM, Laguardia ME, Carbonella DC, Magnani M, Ensoli B, Fattorini L, Cassone A.

FEMS Microbiol Lett. 2006 Sep;262(2):210-5.

41.

Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient.

Meacci F, Orrù G, Iona E, Giannoni F, Piersimoni C, Pozzi G, Fattorini L, Oggioni MR.

J Clin Microbiol. 2005 Jul;43(7):3114-20.

42.

Role of CXCR3 in the immune response to murine gammaherpesvirus 68.

Lee BJ, Giannoni F, Lyon A, Yada S, Lu B, Gerard C, Sarawar SR.

J Virol. 2005 Jul;79(14):9351-5.

43.

Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.

Giannoni F, Iona E, Sementilli F, Brunori L, Pardini M, Migliori GB, Orefici G, Fattorini L.

Antimicrob Agents Chemother. 2005 Jul;49(7):2928-33.

44.

Protein kinase C theta is not essential for T-cell-mediated clearance of murine gammaherpesvirus 68.

Giannoni F, Lyon AB, Wareing MD, Dias PB, Sarawar SR.

J Virol. 2005 Jun;79(11):6808-13. Erratum in: J Virol. 2005 Dec;79(23):15004.

45.

Mycobacterium bovis Bacillus Calmette-Guerin infects DC-SIGN- dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production.

Gagliardi MC, Teloni R, Giannoni F, Pardini M, Sargentini V, Brunori L, Fattorini L, Nisini R.

J Leukoc Biol. 2005 Jul;78(1):106-13. Epub 2005 Apr 21.

PMID:
15845642
46.

Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane.

Giannoni F, Barnett J, Bi K, Samodal R, Lanza P, Marchese P, Billetta R, Vita R, Klein MR, Prakken B, Kwok WW, Sercarz E, Altman A, Albani S.

J Immunol. 2005 Mar 15;174(6):3204-11.

47.

Induction of Mycobacterium avium proteins upon infection of human macrophages.

Brunori L, Giannoni F, Bini L, Liberatori S, Frota C, Jenner P, Thoresen OF, Orefici G, Fattorini L.

Proteomics. 2004 Oct;4(10):3078-83.

PMID:
15378697
48.

In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis.

Fattorini L, Gennaro R, Zanetti M, Tan D, Brunori L, Giannoni F, Pardini M, Orefici G.

Peptides. 2004 Jul;25(7):1075-7.

PMID:
15245864
49.

CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, de Jager W, Pugayung G, Giannoni F, Rijkers G, Albani S, Kuis W, Prakken B.

J Immunol. 2004 May 15;172(10):6435-43.

50.

Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis.

Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, Amox D, Roord S, de Kleer I, Bonnin D, Lanza P, Berry C, Massa M, Billetta R, Albani S.

Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4228-33. Epub 2004 Mar 15.

Supplemental Content

Loading ...
Support Center